Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Glioblastoma Institute
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Brain Cancer

Expert Opinion / Cases · June 01, 2016

Recurrent Glioblastoma

Written by
Julie J. Miller MD, PhD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Julie Miller MD, PhD

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Milton Rabinowits

    Jun 15, 2016

    I will certainly initiate Bevacizumab. She has mild neurological symptoms that can improve immediately with this drug.
There is some evidence that Irinotecan with Bevacizumab could be more active than with temozolomide in unmetilated patients, tha presents poor response to Temozolomide.

  • John Gustavo Reyesvilla Méndez

    Sep 18, 2016

    Why not?, we could give temozolomide and see what happens.

  • Carlos Fardilha

    Apr 03, 2017

    Temozolamide is an option for this patient, despite tumor MGMT promoter was not methylated, there may be benefit. It should be considered [...] irradiation after evaluation of disease progression size and time since last RT course. For this purpose, methionine PET/CT or MR spectroscopy may be helpful.

  • Apr 19, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated